Exploring different approaches to improve the success of drug discovery and development projects: a review

Abstract

Background: There has been a significant increase in the cost and timeline of delivering new drugs for clinical use over the last three decades. Despite the increased investments in research infrastructure by pharmaceutical companies and technological advances in the scientific tools available, efforts to increase the number of molecules coming through the drug development pipeline have largely been unfruitful. Main body: A non-systematic review of the current literature was undertaken to enumerate the various strategies employed to improve the success rates in the pharmaceutical research and development. The review covers the exploitation of genomics and proteomics, complementarity of target-based and phenotypic efficacy screening platforms, drug repurposing and repositioning, collaborative research, focusing on underserved therapeutic fields, outsourcing strategy, and pharmaceutical modeling and artificial intelligence. Examples of successful drug discoveries achieved through application of these strategies are highlighted and discussed herein. Conclusions: Genomics and proteomics have uncovered a wide array of potential drug targets and are facilitative of enhanced scrupulous target identification and validation thus reducing efficacy-related drug attrition. When used complementarily, phenotypic and target-based screening platforms would likely allow serendipitous drug discovery while increasing rationality in drug design. Drug repurposing and repositioning reduces financial risks in drug development accompanied by cost and time savings, while prolonging patent exclusivity hence increased returns on investment to the innovator company. Equally important, collaborative research is facilitative of cross-fertilization and refinement of ideas, while sharing resources and expertise, hence reducing overhead costs in the early stages of drug discovery. Underserved therapeutic fields are niche drug discovery areas that may be used to experiment and launch novel drug targets, while exploiting incentivized benefits afforded by drug regulatory authorities. Outsourcing allows the pharma industries to focus on their core competencies while deriving greater efficiency of specialist contract research organizations. The existing and emerging pharmaceutical modeling and artificial intelligence softwares and tools allow for in silico computation enabling more efficient computer-aided drug design. Careful selection and application of these strategies, singly or in combination, may potentially harness pharmaceutical research and innovation.

A blueprint for high affinity SARS-CoV-2 Mpro inhibitors from activity-based compound library screening guided by analysis of protein dynamics

“…Advanced CADD in combination with high throughput biochemical and phenotypic screening are allowing the rapid evaluation of simulation results and the reduction of time for the discovery of new drugs. 96 The work presented here indeed shows how a computational procedure combined with experimental validation can correctly predict structure and affinity trends of effective hit molecules for a given target. This kind of combined approaches may be a key strategy especially against pandemic viruses and other pathogens, where the immediate identification of effective treatments is of paramount importance.…”

Small Molecules Inhibit Extranuclear Signaling by Estrogen: A Promising Strategy to Halt Breast Cancer Progression and Metastasis

“…The high attrition rate of new chemical entities has been attributed majorly to poor pharmacokinetic profile [25]. The reported ligands have been shown to be drug-like, having satisfied the Lipinski's rule of five [15] and also possess pharmaceutically relevant properties when compared to 95% of orally available drugs [14].…”

Evolving scenario of big data and Artificial Intelligence (AI) in drug discovery

“…After identifying the hit or lead molecules in the drug discovery pipeline, a series of tests and evaluation studies are executed to assess the physicochemical and toxicity properties of the candidate drug molecule. Thus, early identification and weaning of drug candidates with poor physical and chemical properties reduce the failure rate during the drug discovery process [ 157 ]. The AI-based methods aid the execution of this process in a time-efficient manner from a large dataset to effectively predict the physicochemical properties of the compounds [ 158 , 159 ].…”